Respiratory syncytial virus (RSV) in older adults: from infection to outcomes – who gets sick, who gets hospitalized, who survives? Authors: Nefert Candace Dossou, Damiano Cerasuolo, Chloé Dubus, Catherine Francois, Alexandre Réguème, Bénédicte Corroyer, Cécile Schanen, Meriadeg Ar Gouilh, Jean-Christophe Plantier, Remy Morello, Astrid Vabret Published: 2026 ABSTRACT Respiratory syncytial virus (RSV) is a virus responsible for acute respiratory infections and is widely recognized as a major pathogen in the paediatric population. Thus, the burden of RSV in the adult population remains poorly understood, as epidemiological studies mainly rely on PMSI (Medicalization of Information Systems Program) data, which are coded for economic purposes, and because many adults RSV infections remain underdiagnosed. The aim of this study was to describe epidemiological and clinical characteristics of RSV infections in elderly population across four university hospitals in north-western France during the 2022–2023 epidemic season. This retrospective cohort included all patients aged 60 years and older who tested positive for RSV between September 1st, 2022, and January 31st, 2023, in four university hospitals. Viral detection was performed using molecular assays on respiratory samples. Clinical, demographic, biological, and coding data were collected from medical records and hospital information systems. Outcomes included need for oxygen therapy, intensive care admission, in-hospital mortality, length of stay, readmission within 90 days for a respiratory or cardiac reason, and changes in living arrangements. Statistical analyses used descriptive methods and standard tests for comparisons. A total of 647 patients were included. The mean age was 77.8 years, and most patients had at least one chronic medical condition, primarily respiratory or cardiac. 508 (78.5%) patients were hospitalized. The mean hospital stay was 16.2 days, and oxygen therapy was required in 68.3% of cases. In-hospital mortality reached 11.0%. Among survivors, 38.0% were readmitted within 90 days for a respiratory or cardiac reason. A notable proportion of patients experienced a loss of autonomy leading to institutional placement at discharge. RSV was coded in the PMSI database as a diagnosis in approximately two-thirds of hospitalizations, with substantial variations between centers. RSV infection in older adults was associated with significant morbidity, prolonged hospitalization, and a frequent decline in functional status. The study also identified heterogeneity in coding practices and emphasized limitations of PMSI data for capturing respiratory syncytial virus burden. These findings support the need for expanded screening, along with targeted preventive strategies and structured post-discharge follow-up to reduce the long-term burden of RSV in older populations.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12879-026-13693-w. Introduction Respiratory syncytial virus (RSV) (or Orthopneumovirus hominis) [1] is a negative-sense single-stranded RNA respiratory virus belonging to the Pneumoviridae family. It is a virus responsible for acute respiratory infections and is widely recognized as a major pathogen in the paediatric population. Indeed, each year, RSV is estimated to cause over 33 million lower respiratory tract infections (LRTIs), leading to over 3 million hospitalizations of children and more than 100,000 infant deaths [2]. Many epidemiological, clinical, and health-economic studies have highlighted the significant burden of this virus in this population, prompting health authorities worldwide to implement major prevention strategies, including the approval of monoclonal antibodies and vaccines [3–5]. There is also a growing but yet incomplete estimation of the burden associated with RSV infection in adults. A prospective New York study showed that 3% to 7% of patients over 65 years old and 4% to 10% of high-risk patients (with cardiovascular and/or respiratory comorbidities) were infected with RSV each year, leading to 177,000 hospitalizations and over 14,000 deaths [6]. The HARTI study demonstrated that RSV-infected patients required more medical resources than those with influenza infection. Specifically, RSV-infected patients had a longer median hospital length of stay (LOS), a higher proportion of intensive care unit (ICU) admissions, and an increased likelihood of requiring oxygen therapy [7]. These findings were corroborated by two French national database retrospective studies, which using data from the PMSI (Medicalization of Information Systems Program) database, characterized RSV-related hospitalizations and their outcomes in France from 2012 to 2021. These analyses indicated that RSV represented a substantial burden of LRTI-related hospitalizations, with high ICU admission and readmission rates, and mortality similar to that associated with influenza. The burden of RSV also appeared to be greater in patients aged over 60 years [8, 9]. However, these studies have certain limitations. Specifically, it relies on coding practices and virological screening strategies across different French hospitals, making it susceptible to potential underestimations of RSV-related hospitalizations. Thus, the burden of RSV in the adult population remains poorly understood, as epidemiological and economic studies mainly rely on PMSI data, which are coded for economic purposes, and because many adults infected with RSV remain underdiagnosed. Indeed, there is no nationwide policy for expanded RSV screening in the adult population in France. Following the COVID-19 pandemic, the widespread implementation of multiplex PCR assays—including RSV molecular detection—in nearly all routine diagnostic laboratories has created new opportunities to broaden screening and improve the detection of RSV infections in adults [10–12]. Since 2024, three RSV vaccines have been recommended by the FDA (U.S. Food and Drug Administration) for the adult population to prevent severe RSV infections and RSV-related hospitalizations: Arexvy (GSK, GlaxoSmithKline) [13, 14], Abrysvo (Pfizer) [15, 16], mResvia (Moderna) [17, 18]. The CDC (Center for Disease Control and Prevention) recommends vaccination for all adults over 75 years old and for all adults ages 50–74 years old who are at increased risk of severe RSV infections (chronic heart-lung disease, weakened immune system, living in a nursing home, certain other medical conditions). The CDC does not have a preferential recommendation for any specific vaccine. The three vaccines are also authorized for use in the European Union according to the European Medicines Agency (EMA), but their indications differ: Abrysvo is approved for use in adults aged 18 years and older [19], while AREXVY and mRESVIA are both indicated for adults aged 60 years and older. In addition, AREXVY and mRESVIA are also indicated for adults aged 50–59 years and 18–59 years respectively, who are at increased risk of severe RSV disease [20, 21]. In France, since October 2024, these three vaccines are recommended for adults over 75 years old as well as for adults aged 65–74 years with underlying cardiac or respiratory conditions [22]. RSV vaccination has been included in the french national vaccination schedule starting in 2025. However, this vaccination is currently not reimbursed for older adults by the French national health insurance system. The RSV vaccination campaign was first introduced in the United States during the 2023–2024 season, and the initial results appear to be promising. Indeed, a study conducted across eight U.S. states demonstrated that vaccination was highly effective in reducing hospitalizations associated with RSV among adults aged 60 years and older. The estimated vaccine effectiveness was approximately 80% (95% CI: 71–85) among individuals without immunodeficiency and about 73% (95% CI: 48–85) among immunocompromised adults [23]. Similarly, in England, a vaccination campaign was initiated during the 2023–2024 season with a recommendation targeting only adults aged 75–79 years. A study published in 2025 reported the results of this campaign, showing an approximately 30% reduction in RSV-related hospitalizations, corresponding to an estimated vaccine effectiveness of nearly 70%. Despite a relatively limited vaccine coverage (~ 45%), these findings suggest a significant protective effect within the first months following implementation. However, the authors note that follow-up period remains short and emphasize the need for further analyses to confirm these early observations over the longer term [24]. In this context, French data will be essential to assess the impact of the upcoming French national vaccination campaign and to guide its optimization. These new vaccination strategies in the elderly population must be supported by comprehensive epidemiological and clinical studies to ensure a more accurate definition and confirmation of RSV vaccine target groups among adults. Our study aims to epidemiologically and clinically characterize all patients over 60 years of age, infected with RSV, and admitted to a university hospital center in the French north-western region (Amiens, Caen, Lille, Rouen University Hospitals) during the 2022–2023 autumn-winter epidemic season. Although the study period corresponds to the post-COVID-19 era, it was primarily selected because all four participating centers were equipped with multiplex PCR assays that included RSV. During this period, each center had implemented locally defined, expanded COVID-19 screening strategies using these multiplex tests. Depending on the site, these strategies involved either systematic testing of all patients admitted through the emergency department or systematic testing of all hospitalized patients, regardless of symptoms. While these strategies were primarily intended for SARS-CoV-2 detection, they also enabled incidental RSV detection, thereby offering a valuable opportunity to assess RSV circulation in a real-world context of broad respiratory virus testing. These data will be compared with the PMSI database to describe coding practices for RSV infections and highlight the limitations of using these data for epidemiological studies. Finally, the collection and analysis of epidemiological data in the post-COVID-19 pandemic period will provide a valuable reference for future epidemiological studies conducted after the implementation of vaccination programs. Materials and methods Study design This was a retrospective cohort study included patients aged 60 years and older who were diagnosed with RSV infection during the 2022–2023 winter epidemic season in one of four university hospital centers: Amiens University Hospital, Caen University Hospital, Lille University Hospital, and Rouen University Hospital. The inclusion period extended from September 1st, 2022, to January 31st, 2023, corresponding to the local RSV epidemic season. RSV-case selection All patients over 60 years old who tested positive for RSV during the study period were retrospectively included. Diagnosis of RSV infection was biological and based on a virological molecular detection test performed on respiratory specimens. All tests used reverse transcription polymerase chain reaction-based technology, though they did not always enable the typing of RSV into subgroups A or B. Viral testing, medical management, or decisions to hospitalize the patients were made according to local standard-of-care (SOC) practices. Two patient groups were defined for the purposes of the study: Patients who were hospitalized (In-patients) and those managed exclusively in the emergency department (Out-patients). The four inclusion centers had different screening strategies. Centers 2 and 4 screened patients from the emergency department and therefore included both inpatients and outpatients. Centers 1 and 3 screened almost exclusively hospitalized patients and therefore included predominantly inpatients. Data collection Social, demographic, and clinical data were extracted from medical records and anonymized in accordance with confidentiality requirements. Biological data were obtained from the computerized information systems of the virology laboratories in the four hospital centers. The patients’ diagnoses were coded by physicians according to the WHO 10th International Classification of Diseases (ICD-10), as primary diagnoses (PD) for the reason for hospitalization, related diagnoses (RD) for any underlying condition, and/or significantly associated diagnoses (SAD) for comorbidities or complications. These coding data were extracted from the PMSI database, the French National Hospital information system. In this study, a hospitalization was considered as RSV-coded if one of the following codes was recorded as PD, RD and/or SAD: J20.5 (Acute bronchitis due to RSV), J21.0 (acute bronchiolitis due to RSV), J12.1 (pneumonia due to RSV), or B97.4 (RSV as the cause of disease classified elsewhere, as SAD only). All chronic underlying medical conditions recognized as risk factors for RSV-related outcomes were identified: chronic kidney diseases, chronic cardiac diseases, chronic respiratory diseases (asthma, COPD (Chronic Obstructive Pulmonary Disease) or others), diabetes, and immunodeficiency. Patient outcomes were assessed based on length of hospital-stay (LOS), need for oxygen therapy, all-cause in-hospital mortality, need for intensive care (admission to an intensive care unit (ICU) or reanimation) during stay, and readmission within 90 days after discharge for cardiac and/or respiratory reason. To assess the impact of RSV infection on patient autonomy, living arrangements before and after hospital admission were compared (institutional care, living at home with family and/or a partner, or living alone independently at home). Statistical analysis The objective of this study is pre-eminently descriptive. Patients’ characteristics were described by hospital stay (outpatient or inpatient) and by hospital center, by outcomes and by diagnosis. Qualitative variables were expressed as absolute and relative frequencies. Association between patient characteristics or hospital stay and cardiac or respiratory co-morbidities were assessed using Pearson’s χ² test. When expected cell frequencies were below 5, Fisher’s exact test was used instead. For χ² tests with sparse data, p-values were obtained through Monte Carlo simulation with 2,000 to 10,000 replicates. All statistical tests were two-sided, with a significance level set at α = 0.05. Quantitative variables were described using means and standard deviations for normally distributed data, or medians and interquartile ranges (IQR) for non-normally distributed data. Normality was assessed using the Shapiro-Wilk test. No method to impute missing data has been used in this analysis. All analysis were performed on R and R Studio, version 2025.09.1, ‘Cucumberleaf Sunflower’ Release. Results Study population A total of 652 patients aged over 60 years tested positive for RSV during the study period (September 1st 2022 – January 31st 2023). Among them, five patients were excluded in the study due to insufficient available data. Of the total diagnoses, 638 were made using upper respiratory tract specimens, while 9 were based on lower respiratory tract specimens. Centers 2 and 4 accounted for the highest number of included participants. The first patient was enrolled on September 15, 2022. A marked increase in case inclusion was observed in December, particularly during the second half of the month (Fig. 1). Fig. 1Daily number of RSV diagnoses among patients aged over 60 years old during the 2022–2023 epidemic season across the four university hospitals. Each grey bar represents the number of patients diagnosed with RSV on a given day. The distribution highlights temporal trends and potential epidemic peaks over the study period. Each colored curve represents the average number of diagnosed RSV cases for each center using a 5-day sliding window Daily number of RSV diagnoses among patients aged over 60 years old during the 2022–2023 epidemic season across the four university hospitals. Each grey bar represents the number of patients diagnosed with RSV on a given day. The distribution highlights temporal trends and potential epidemic peaks over the study period. Each colored curve represents the average number of diagnosed RSV cases for each center using a 5-day sliding window The mean age was 77.8 +/- 10.1 years, with a slight female predominance (53.2%). 40.7% of patients belonged to the 60–75 age group, 28.6% to the 75–85 group, and 30.6% were aged 85 years and older. At least one chronic underlying medical condition was found in 97.5% of them, mainly chronic respiratory diseases (66.8%) and chronic cardiac diseases (64.5%). Indeed, the main reason for presentation to the hospital, as reported in the medical records, was a cardiorespiratory condition (329 patients), primarily dyspnea and/or decompensation of chronic cardiac or respiratory diseases. Notably, 35 patients (5.4%) were admitted following a fall or a fall-related fracture. (Table 1). Among the 647 included patients, 508 (78.5%) were hospitalized, with variations observed between centers, likely due to differences in local screening policies. The age distribution was relatively similar across out-patients and in-stay-patients (Table 1). Table 1Characteristics of included RSV-positive patients aged over 60 years oldOverallCenter n°1Center n°2Center n°3Center n°4Out-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patients n 1395081505415838781213Age, mean (sd)78.5 (10.1)77.6 (10.1)82.077.0 (10.5)79.1 (10.7)77.9 (10.4)69.0 (7.8)76.5 (9.6)78.4 (9.7)78.0 (10.1)Age groups, n (%)[60–75[53 (38.1)210 (41.4)0 (0.0)20 (40.0)19 (35.2)66 (41.8)2 (66.7)43 (49.4)32 (39.5)81 (38.0)[75–85[40 (28.8)145 (28.6)1 (100.0)15 (30.0)15 (27.8)48 (30.4)1 (33.3)21 (24.1)23 (28.4)61 (28.6)[85–101]46 (33.1)152 (30.0)0 (0.0)15 (30.0)20 (37.0)44 (27.8)0 (0.0)23 (26.4)26 (32.1)70 (32.9) Missing 0 1 0 0 0 0 0 0 0 1 Sex, n (%)Female74 (53.2)270 (53.1)1 (100.0)27 (54.0)32 (59.3)86 (54.4)2 (66.7)42 (48.3)39 (48.1)115 (54.0)Male65 (46.8)238 (46.9)0 (0.0)23 (46.0)22 (40.7)72 (45.6)1 (33.3)45 (51.7)42 (51.9)98 (46.0)Chronic kidney disease, n (%)No99 (77.3)380 (79.7)1 (100.0)38 (80.9)37 (77.1)114 (76.0)3 (100.0)68 (79.1)58 (76.3)160 (82.5)Yes29 (22.7)97 (20.3)0 (0.0)9 (19.1)11 (22.9)36 (24.0)0 (0.0)18 (20.9)18 (23.7)34 (17.5) Missing 11 31 0 3 6 8 0 1 5 19 Chronic cardiac disease, n (%)No41 (32.0)154 (31.8)0 (0.0)22 (44.9)8 (16.3)21 (13.6)1 (50.0)36 (42.4)32 (42.1)75 (38.3)Yes87 (68.0)330 (68.2)1 (100.0)27 (55.1)41 (83.7)133 (86.4)1 (50.0)49 (57.6)44 (57.9)121 (61.7) Missing 11 24 0 1 5 4 1 2 5 17 Chronic respiratory disease, n (%)No31 (23.5)156 (32.0)0 (0.0)30 (65.2)29 (59.2)83 (53.9)1 (33.3)40 (48.2)1 (1.3)3 (1.5)Yes101 (76.5)331 (68.0)0 (0.0)16 (34.8)20 (40.8)71 (46.1)2 (66.7)43 (51.8)79 (98.8)201 (98.5) Missing 7 21 1 4 5 4 0 4 1 9 Diabetes, n (%)No91 (71.7)325 (67.4)1 (100.0)31 (63.3)28 (59.6)95 (62.9)2 (66.7)61 (70.9)60 (78.9)138 (70.4)Yes36 (28.3)157 (32.6)0 (0.0)18 (36.7)19 (40.4)56 (37.1)1 (33.3)25 (29.1)16 (21.1)58 (29.6) Missing 12 26 0 1 7 7 0 1 5 17 Immunodeficiency, n (%)No112 (80.6)389 (76.6)1 (100.0)43 (86.0)50 (92.6)131 (82.9)2 (66.7)50 (57.5)59 (72.8)165 (77.5)Yes27 (19.4)119 (23.4)0 (0.0)7 (14.0)4 (7.4)27 (17.1)1 (33.3)37 (42.5)22 (27.2)48 (22.5)Reasons for hospital admission, n (%)General Health Deterioration19 (14.1)32 (8.3)0 (0.0)4 (8.0)3 (5.7)5 (4.0)0 (0.0)0 (0.0)16 (19.8)23 (11.1)Cardiorespiratory reason87 (64.4)242 (63.0)1 (100.0)42 (84.0)37 (69.8)84 (66.7)0 (0.0)0 (0.0)49 (60.5)116 (55.8)Neurovascular reason5 (3.7)13 (3.4)0 (0.0)0 (0.0)4 (7.5)11 (8.7)0 (0.0)0 (0.0)1 (1.2)2 (1.0)Orthopaedic and/or trauma-related reasons5 (3.7)30 (7.8)0 (0.0)1 (2.0)5 (9.4)20 (15.9)0 (0.0)0 (0.0)0 (0.0)9 (4.3)Others19 (14.1)67 (17.4)0 (0.0)3 (6.0)4 (7.5)6 (4.8)0 (0.0)0 (0.0)15 (18.5)58 (27.9) Missing 4 124 0 0 1 32 3 87 0 5 Abbreviations: SD, standard deviationOut-patients: Patients managed exclusively in the emergency department without in-patient admissionIn-patients: Patients with in-patient admissionImmunodeficiency: Includes any form of mild to severe immunodeficiency, whether congenital or acquiredReasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Table 1Characteristics of included RSV-positive patients aged over 60 years oldOverallCenter n°1Center n°2Center n°3Center n°4Out-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patientsOut-patientsIn-patients n 1395081505415838781213Age, mean (sd)78.5 (10.1)77.6 (10.1)82.077.0 (10.5)79.1 (10.7)77.9 (10.4)69.0 (7.8)76.5 (9.6)78.4 (9.7)78.0 (10.1)Age groups, n (%)[60–75[53 (38.1)210 (41.4)0 (0.0)20 (40.0)19 (35.2)66 (41.8)2 (66.7)43 (49.4)32 (39.5)81 (38.0)[75–85[40 (28.8)145 (28.6)1 (100.0)15 (30.0)15 (27.8)48 (30.4)1 (33.3)21 (24.1)23 (28.4)61 (28.6)[85–101]46 (33.1)152 (30.0)0 (0.0)15 (30.0)20 (37.0)44 (27.8)0 (0.0)23 (26.4)26 (32.1)70 (32.9) Missing 0 1 0 0 0 0 0 0 0 1 Sex, n (%)Female74 (53.2)270 (53.1)1 (100.0)27 (54.0)32 (59.3)86 (54.4)2 (66.7)42 (48.3)39 (48.1)115 (54.0)Male65 (46.8)238 (46.9)0 (0.0)23 (46.0)22 (40.7)72 (45.6)1 (33.3)45 (51.7)42 (51.9)98 (46.0)Chronic kidney disease, n (%)No99 (77.3)380 (79.7)1 (100.0)38 (80.9)37 (77.1)114 (76.0)3 (100.0)68 (79.1)58 (76.3)160 (82.5)Yes29 (22.7)97 (20.3)0 (0.0)9 (19.1)11 (22.9)36 (24.0)0 (0.0)18 (20.9)18 (23.7)34 (17.5) Missing 11 31 0 3 6 8 0 1 5 19 Chronic cardiac disease, n (%)No41 (32.0)154 (31.8)0 (0.0)22 (44.9)8 (16.3)21 (13.6)1 (50.0)36 (42.4)32 (42.1)75 (38.3)Yes87 (68.0)330 (68.2)1 (100.0)27 (55.1)41 (83.7)133 (86.4)1 (50.0)49 (57.6)44 (57.9)121 (61.7) Missing 11 24 0 1 5 4 1 2 5 17 Chronic respiratory disease, n (%)No31 (23.5)156 (32.0)0 (0.0)30 (65.2)29 (59.2)83 (53.9)1 (33.3)40 (48.2)1 (1.3)3 (1.5)Yes101 (76.5)331 (68.0)0 (0.0)16 (34.8)20 (40.8)71 (46.1)2 (66.7)43 (51.8)79 (98.8)201 (98.5) Missing 7 21 1 4 5 4 0 4 1 9 Diabetes, n (%)No91 (71.7)325 (67.4)1 (100.0)31 (63.3)28 (59.6)95 (62.9)2 (66.7)61 (70.9)60 (78.9)138 (70.4)Yes36 (28.3)157 (32.6)0 (0.0)18 (36.7)19 (40.4)56 (37.1)1 (33.3)25 (29.1)16 (21.1)58 (29.6) Missing 12 26 0 1 7 7 0 1 5 17 Immunodeficiency, n (%)No112 (80.6)389 (76.6)1 (100.0)43 (86.0)50 (92.6)131 (82.9)2 (66.7)50 (57.5)59 (72.8)165 (77.5)Yes27 (19.4)119 (23.4)0 (0.0)7 (14.0)4 (7.4)27 (17.1)1 (33.3)37 (42.5)22 (27.2)48 (22.5)Reasons for hospital admission, n (%)General Health Deterioration19 (14.1)32 (8.3)0 (0.0)4 (8.0)3 (5.7)5 (4.0)0 (0.0)0 (0.0)16 (19.8)23 (11.1)Cardiorespiratory reason87 (64.4)242 (63.0)1 (100.0)42 (84.0)37 (69.8)84 (66.7)0 (0.0)0 (0.0)49 (60.5)116 (55.8)Neurovascular reason5 (3.7)13 (3.4)0 (0.0)0 (0.0)4 (7.5)11 (8.7)0 (0.0)0 (0.0)1 (1.2)2 (1.0)Orthopaedic and/or trauma-related reasons5 (3.7)30 (7.8)0 (0.0)1 (2.0)5 (9.4)20 (15.9)0 (0.0)0 (0.0)0 (0.0)9 (4.3)Others19 (14.1)67 (17.4)0 (0.0)3 (6.0)4 (7.5)6 (4.8)0 (0.0)0 (0.0)15 (18.5)58 (27.9) Missing 4 124 0 0 1 32 3 87 0 5 Abbreviations: SD, standard deviationOut-patients: Patients managed exclusively in the emergency department without in-patient admissionIn-patients: Patients with in-patient admissionImmunodeficiency: Includes any form of mild to severe immunodeficiency, whether congenital or acquiredReasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Characteristics of included RSV-positive patients aged over 60 years old Abbreviations: SD, standard deviation Out-patients: Patients managed exclusively in the emergency department without in-patient admission In-patients: Patients with in-patient admission Immunodeficiency: Includes any form of mild to severe immunodeficiency, whether congenital or acquired Reasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Table 2Distribution of ICD-10 codes for RSV-related diagnoses according to centers, reasons for hospital admission, and length of stayPneumoniae due to RSV (J12.1)Acute bronchitis due to RSV (J20.5)Acute bronchiolitis due to RSV (J21.0)RSV as a cause of disease classified elsewhere (B97.4)p-values138145155Center, n (%)< 0.001Center n°113 (9.4)1 (7.1)1 (20.0)24 (15.5)Center n°241 (29.7)6 (42.9)2 (40.0)57 (36.8)Center n°334 (24.6)0 (0.0)1 (20.0)0 (0.0)Center n°450 (36.2)7 (50.0)1 (20.0)74 (47.7)Reasons for hospital admission, n (%)< 0.001General Health Deterioration11 (10.9)1 (7.1)0 (0.0)11 (7.7)Cardiorespiratory reason81 (80.2)10 (71.4)2 (50.0)97 (67.8)Neurovascular reason2 (2.0)0 (0.0)0 (0.0)5 (3.5)Orthopedic and/or trauma-related reasons1 (1.0)0 (0.0)0 (0.0)3 (2.1)Other reasons6 (5.9)3 (21.4)2 (50.0)27 (18.9) Missing 37 0 1 12 Overall length of stay 0.935Days, mean (sd)24.6 (158.9)7.0 (4.1)8.8 (3.7)22.9 (34.6)< 7 days55 (42.6)6 (46.2)1 (20.0)32 (21.2)≥ 7 days74 (57.4)7 (53.8)4 (80.0)119 (78.8)Abbreviations: SD, standard deviationReasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Table 2Distribution of ICD-10 codes for RSV-related diagnoses according to centers, reasons for hospital admission, and length of stayPneumoniae due to RSV (J12.1)Acute bronchitis due to RSV (J20.5)Acute bronchiolitis due to RSV (J21.0)RSV as a cause of disease classified elsewhere (B97.4)p-values138145155Center, n (%)< 0.001Center n°113 (9.4)1 (7.1)1 (20.0)24 (15.5)Center n°241 (29.7)6 (42.9)2 (40.0)57 (36.8)Center n°334 (24.6)0 (0.0)1 (20.0)0 (0.0)Center n°450 (36.2)7 (50.0)1 (20.0)74 (47.7)Reasons for hospital admission, n (%)< 0.001General Health Deterioration11 (10.9)1 (7.1)0 (0.0)11 (7.7)Cardiorespiratory reason81 (80.2)10 (71.4)2 (50.0)97 (67.8)Neurovascular reason2 (2.0)0 (0.0)0 (0.0)5 (3.5)Orthopedic and/or trauma-related reasons1 (1.0)0 (0.0)0 (0.0)3 (2.1)Other reasons6 (5.9)3 (21.4)2 (50.0)27 (18.9) Missing 37 0 1 12 Overall length of stay 0.935Days, mean (sd)24.6 (158.9)7.0 (4.1)8.8 (3.7)22.9 (34.6)< 7 days55 (42.6)6 (46.2)1 (20.0)32 (21.2)≥ 7 days74 (57.4)7 (53.8)4 (80.0)119 (78.8)Abbreviations: SD, standard deviationReasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Distribution of ICD-10 codes for RSV-related diagnoses according to centers, reasons for hospital admission, and length of stay Abbreviations: SD, standard deviation Reasons for hospital admission: Reason for hospital visit as reported in the patient’s medical record. This is independent of the ICD-10 coding reported in the PMSI database Treatments and outcomes The mean LOS was 16.2 +/- 25.3 days, with a median of 7.1 days. Overall, 60.8% of patients had a stay longer than 7 days. Oxygen therapy was required in 68.3% of cases, and 8.7% of patients required intensive care. The in-hospital mortality rate was 11.0% (mean age at death: 81.0 +/- 10.3), and among the 453 survivors, 38.0% of patients were readmitted within 90 days for a cardiac and/or respiratory reason (Supplementary data – Table X1). Patient outcomes were more severe among those with at least a respiratory comorbidity, with a significantly higher proportion experiencing hospital stays longer than 7 days (Fig. 2a, Supplementary data – Table X1). The main respiratory comorbidities were COPD and chronic respiratory failure. A trend toward a higher frequency of outcomes was also observed in patients with a cardiac or a renal comorbidity compared to those without, but no significant difference was found (Fig. 2b and c, Supplementary data – Table X1). Similarly, men seemed to have longer hospital stays and higher mortality rates than women; this difference was more pronounced among patients aged over 75 years (Supplementary data – Table X2). Fig. 2Clinical outcomes according to the presence or absence of respiratory (A), cardiac (B) or renal (C) comorbidities. Bars represent the proportion of patients presenting clinical outcomes according to whether or not they have respiratory (A), cardiac (B) or renal (C) comorbidities. P-values are shown above the comparisons. Oxygen therapy: Need for oxygen therapy during stay. ICU admission: Admission to an intensive care or reanimation unit during stay. Mortality: All-cause-in-hospital mortality. > 7 days stay: In-hospital stay longer than 7 days. Readmission: Readmission within 90 days after discharge for a cardiac and/or respiratory reason Clinical outcomes according to the presence or absence of respiratory (A), cardiac (B) or renal (C) comorbidities. Bars represent the proportion of patients presenting clinical outcomes according to whether or not they have respiratory (A), cardiac (B) or renal (C) comorbidities. P-values are shown above the comparisons. Oxygen therapy: Need for oxygen therapy during stay. ICU admission: Admission to an intensive care or reanimation unit during stay. Mortality: All-cause-in-hospital mortality. > 7 days stay: In-hospital stay longer than 7 days. Readmission: Readmission within 90 days after discharge for a cardiac and/or respiratory reason RSV infection and greater care dependency A substantial proportion of patients (12.9%), especially those aged 75 and older, experienced a loss of autonomy, with many transitioning from home (either alone or with family) to institutional care following hospitalization. The risk of adverse discharge outcomes increases with age. Older patients are less likely to return to their previous living situation, particularly those who lived alone prior to admission. Patients admitted to the hospital while living with family or a partner are more likely to return to the same arrangement, particularly in the younger age groups (60–64 and 65–74), indicating a buffering role of social support (Fig. 3). Among patients who transitioned from home to an institution at discharge, the mean age was 80.7 +/- 10.3 years. These patients had a longer average LOS compared to others (35.9 +/- 37.6, p-value < 0.001), with 92.5% of them experiencing a stay longer than 7 days. This difference in LOS could be partly explained by variable waiting times for institutional placement (Supplementary data – Table X3). 84.6% of them had an RSV-associated hospital stay with an ICD-10 code related to an RSV infection. The remaining patients had hospitalizations coded for conditions such as consequences of falls or fractures at home, LRTI without specified aetiology, or cardiac decompensation — all of which are conditions that may be associated with RSV. These findings suggest the potential impact of RSV on the loss of autonomy and/or the acceleration of functional decline in patients (Supplementary data – Table X3). Fig. 3Discharge destinations following hospitalizations by Age and pre-admission living arrangement.This Sankey diagram illustrates the transitions in living arrangements stratified by age groups, from entry to discharge. The three age groups considered are 60–64 (green), 65–74 (pink), and over 74 years (blue). Each flow represents individuals moving from a specific type of living arrangement at entry (left) to another arrangement at discharge (right). The thickness of each flow is proportional to the number of individuals within each transition. The figure is based on data from 325 patients for whom information on both entry and discharge living arrangements was complete Discharge destinations following hospitalizations by Age and pre-admission living arrangement.This Sankey diagram illustrates the transitions in living arrangements stratified by age groups, from entry to discharge. The three age groups considered are 60–64 (green), 65–74 (pink), and over 74 years (blue). Each flow represents individuals moving from a specific type of living arrangement at entry (left) to another arrangement at discharge (right). The thickness of each flow is proportional to the number of individuals within each transition. The figure is based on data from 325 patients for whom information on both entry and discharge living arrangements was complete RSV-coded in-stay: RSV-associated hospitalisations vs. Non-RSV associated hospitalisations In 65.8% of cases (n = 312), RSV was assigned as a diagnosis according to the PMSI database. Specifically, in 157 patients, RSV was recorded as the PD with the following codes: J12.1 (pneumonia due to RSV), J20.5 (acute bronchitis due to RSV), and J21.0 (acute bronchiolitis due to RSV). In 155 patients, RSV was recorded as a SAD, most often in the context of cardiovascular failure. However, heterogeneity was observed in coding practices and in the types of codes used for RSV diagnosis across centers (Tables 1 and 2). In 34.2% of cases, RSV was not assigned as a diagnosis in the PMSI database. Among these patients, 22.8% (39) had a PD code belonging to chapter I of the ICD-10 classification (diseases of the circulatory system), while 24.7% (40) had a PD code from chapter J (diseases of the respiratory system). Overall, 44.4% of them had a viral respiratory infection assigned as PD (without mention of RSV), while 11.7% had a confusion, fall, and/or fracture secondary to confusion assigned as a PD (Fig. 4) Fig. 4Distribution of primary diagnosis codes in patients without RSV coding. Distribution of primary diagnosis codes among patients for whom RSV was not coded as a diagnosis. Bars represent ICD-10 chapter I (diseases of the circulatory system), chapter J (diseases of the respiratory system), and all other chapters. Within each bar, sections are color-coded to indicate the proportion of patients with a diagnosis suggestive of viral respiratory infection (red), confusion or fall/fracture secondary to confusion (blue), or other diagnoses (grey) Distribution of primary diagnosis codes in patients without RSV coding. Distribution of primary diagnosis codes among patients for whom RSV was not coded as a diagnosis. Bars represent ICD-10 chapter I (diseases of the circulatory system), chapter J (diseases of the respiratory system), and all other chapters. Within each bar, sections are color-coded to indicate the proportion of patients with a diagnosis suggestive of viral respiratory infection (red), confusion or fall/fracture secondary to confusion (blue), or other diagnoses (grey) Discussion A major strength of our study lies in its near-exhaustive RSV infection case capture, achieved through the inclusion of all patients with laboratory-confirmed RSV during a period of near-systematic admission screening. Most previous epidemiological studies have relied on administrative databases such as PMSI, despite the well-known limitations of this approach. Indeed, RSV identification through ICD-10 codes can reach a very high specificity (99.8%) but a strikingly low sensitivity of only 6%, which can drop to as low as 1.7% in patients over 65 years old [25, 26]. The lack of systematic RSV screening recommendations in older adults leads to substantial underdiagnosis. And without diagnosis, there can be no coding. In contrast, our results showed coding rates exceeding 65% in this older population and during a period of near-systematic admission screening, although coding practices varied significantly between centers (Table 2). This variability may partly reflect differences in local coding practices, as the individuals responsible for coding are not the same across hospitals—ranging from medical staff to dedicated administrative personnel—potentially leading to variations in diagnostic interpretation and code assignment. Another plausible explanation is the medico-economic purpose of coding, which may encourage the preferential recording of PD that provide financial advantages to the institution or the specific department. Moreover, a substantial proportion of patients with a diagnosis code of viral respiratory infection still lacked an RSV-specific code (Fig. 4), which may reflect a possible misapplication of the coding system, with the use of codes indicating hospitalization for viral respiratory infection without applying the specific RSV codes. Taken together, these findings highlight that while PMSI data may serve as a useful complementary tool, it remains insufficiently sensitive to reliably capture RSV burden in older populations, underscoring the added value of our study design. In our study population, the mean LOS was 16.2 days, exceeding values typically reported in the literature [8–9, 26–29]. Similarly, the in-hospital mortality rate was 11.0%, also higher than previously documented [8–9, 30]. Several factors may explain these differences. First, our cohort benefited from a more exhaustive case capture, including patients hospitalized for RSV-related complications such as cardiovascular failure, in whom RSV was not always coded despite being a causal factor. These patients usually required longer hospital management. In addition, a substantial proportion of our patients had to be transferred to other institutions, likely facing delays before admission, which may also have contributed to the longer overall LOS observed in our study. At least one chronic medical condition was found in 97.5% of cases, a proportion consistent with previous reports in the literature (ranging from 50% to 97%) [27–29]. A large proportion of patients had a PD related to a failure of a pre-existing cardiac and/or respiratory disease, with or without RSV coded as SAD (Fig. 4). This pattern suggests that hospitalizations were often primarily driven by cardiorespiratory conditions, possibly reflecting failure of underlying diseases triggered by RSV infection. The principal contribution of this study lies in demonstrating the potential functional impact of RSV infection among older adults, often triggering a shift toward greater care dependency, especially in the most elderly and socially isolated individuals. In our study, RSV was associated with transfer to an institution at hospital discharge in some cases. The risk of adverse discharge outcomes increases with age. This study has some limitations. First, RSV subtyping was not performed, therefore preventing assessment of the potential impact of viral subtype on the observed outcomes. Second, due to the retrospective design, some frailty indicators were not available for collection or calculation, such as body mass index (BMI), the Charlson Comorbidity Index, or the Triage Risk Screening Tool (TRST). As a result, our analyses could not be weighted according to patient frailty, which may have influenced the interpretation of outcomes in this particularly vulnerable population. In addition, possible bias cannot be excluded regarding the comorbidities: some comorbidities may not have been declared by the patient or detected by healthcare professionals at the time of hospital admission. Certain comorbidities may have been previously unrecognized and only diagnosed during the RSV infection episode. The impact of viral and/or bacterial co-detections or co-infections could not be assessed in this study. Although most patients were tested using multiplex PCR assays, these were most often limited to triplex panels (Influenza, RSV, and SARS-CoV-2), which did not allow for broader viral screening. Similarly, the investigation of bacterial co-infections was not performed, as this was a retrospective study and bacterial etiological testing is not routinely conducted, even in the presence of suggestive clinical symptoms. Finally, recent years have highlighted potential variability in RSV seasonality, likely influenced by changes in population immunity following the COVID-19 pandemic and the implementation of non-pharmaceutical interventions [31]. But based on our data for the 2022–2023 season, we still observed a winter peak in December in the older adult population. Ongoing surveillance will thus be essential to better understand these post-COVID-19 pandemic dynamics, particularly in the context of the progressive introduction of RSV vaccination and other preventive strategies. Conclusion Our results highlight the major role of RSV in elderly as a cause of respiratory infections, not only leading to cardiovascular failures but also to prolonged hospitalizations, elevated in-hospital mortality, and a substantial risk of readmission. This study also highlights the limitations and potential misuses of the ICD-10 classification, as well as the possible biases due to its medico-economic applications. Even considering a likely underestimation of patient frailty, these findings reinforce the urgent need for expanded screening of RSV, along with targeted preventive strategies and structured post-discharge follow-up to reduce the long-term burden of RSV in older populations. They also emphasize the importance of conducting a dedicated prospective study allowing follow-up of patients infected with RSV, as well as with other circulating viral and/or bacterial respiratory pathogens. Importantly, in the context of the progressive implementation of RSV vaccination in older adults, these baseline data will be essential to assess the real-world impact of RSV vaccination strategies on morbidity, healthcare utilization, and mortality. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1